Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-471 (Vepdegestrant) effect on Dabigatran PK in healthy adults
NCT05673889Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration of Total Dabigatran and Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time of Total Dabigatran. Started Jan 2023; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05673889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673889.